Cambridge Healthtech Institute’s 16th Annual
DRIVING CLINICAL SUCCESS IN ANTIBODY-DRUG CONJUGATES
Designing the Magic Bullet
May 14-15, 2026
The ADC field has seen remarkable breakthroughs, with new approvals including datopotamab deruxtecan (Dato-DXd), Gemcitabine intravesical system (Inlexzo), and Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) this year. These new approvals represent a new generation of ADCs with improved linker-payload technologies that achieve better therapeutic windows, and open the door to pan-cancer approaches and earlier treatment sequence. Innovations in ADC engineering, novel payload types, new MOAs and targets are improving efficacy and reducing off-target toxicity. Newer ADCs with bispecificity, dual payloads, and immunostimulatory functions are emerging to overcome tumor heterogeneity and drug resistance in refractory cancers. Join us at Cambridge Healthtech Institute's 16th annual Driving Clinical Success in ADCs conference to discover and hear about these innovations that are driving the future success in ADCs.
ENGINEERING INNOVATIONS—OPTIMIZING FOR SAFETY, EFFICACY, AND BETTER THERAPEUTIC INDEX
- Site-Specific ADC conjugation—moving beyond traditional lysine and cysteine conjugation to engineered sites
- Fc-gamma receptor binding
- Novel Linkers for selective cleavage and reduced toxicity
NOVEL ADC PLATFORMS AND MECHANISMS OF ACTION
- Bispecific ADC to improve internalization
- Dual Payload ADCs
- Antibody-Oligonucleotide Conjugates (AOCs)
- Cytokine ADCs, and novel scaffold-based conjugates
- Degrader-Antibody conjugates (DAC)
- ISACs/Immune-activating ADCs
- Ultra-high DAR Platforms for Low-Potency Warheads
NOVEL TARGETS AND ADCs IN THE CLINIC
- CDH6, Napi2b, ROR1, CD123, SEZ6, DLL3
CASE STUDIES AND LESSONS LEARNED FROM RECENT APPROVALS
- ZIHERA, Datroway, Emrelis, HER3-DXd
The deadline for priority consideration is October 31, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: